Revvity, Inc. · NYSE:RVTY
Revvity — PerkinElmer — Q3 2021 Earnings Presentation
7 slides from Revvity's earnings presentation, Nov 2, 2021
Slide 1: 3Q21 Earnings Presentation
3Q21 Earnings Presentation November 2, 2021
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: 3Q '21 Financial Results
3Q ‘21 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights Growth 12% Margin 80bps Growth 11% DAS Adjusted Revenue: $1.17 billion; +21% y/y 44% +DD • Organic: +12%; M&A: +8%; FX: +1% DX 56% • COVID: $302 million vs. $288 million in 3Q20 +DD • Non-COVID: +16% organic
Slide 4: Discovery & Analytical Solutions
DISCOVERY & ANALYTICAL SOLUTIONS 3Q21 Performance ✓ DD organic growth with Pharma/Biotech Food* Life up DD and Acad/Gov’t up MSD Sciences ✓ Discovery (+DD) driven by strength in • +21% reported growth reagents & imaging/detection • Organic: +10%; M&A: +10%; FX: +1% • DD organic growth in Americas &
Slide 5: Diagnostics
DIAGNOSTICS 3Q21 Performance ✓ DD organic growth driven by clinical Applied Reproductive diagnostics franchise Genomics Health • +21% reported growth ✓ Ongoing birth rate pressures offset by ImmunoDx improved utilization & menu expansion • Organic: +13%; M&A: +7%; FX: +2% • Non-COVID diagnostics +25
Slide 6: Updated Financial Guidance
UPDATED FINANCIAL GUIDANCE 4Q21 Guidance 2021 Guidance • Adjusted Revenue: $1.2 billion; -10% reported • Adjusted Revenue: $4.9 billion; +30% reported growth • Organic: -22%; M&A +11%; FX +0% • Organic: +20%; M&A +8%; FX +2% Assumptions COVID vs. Non-COVID Outlook Assumptions COVID vs. Non-COVID Out
Slide 7: Innovating for a healthier world
INNOVATING for a healthier world Steve Willoughby | Vice President, Investor Relations | steve.willoughby@perkinelmer.com 7